{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:05:26Z","timestamp":1768928726501,"version":"3.49.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>EPHESUS was a multicentre, double-blind clinical trial in which 6632 patients with acute myocardial infarction (AMI) complicated by LV systolic dysfunction (LVSD) were randomized to receive eplerenone (n = 3319) or placebo (n = 3313). A total of 1580 EPHESUS patients were treated with PCI, which is now the standard treatment for AMI. This EPHESUS substudy examined the effects of eplerenone upon cardiovascular outcomes in PCI-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>EPHESUS patients were divided into PCI-treated and non-PCI-treated cohorts, and the effect of eplerenone upon mortality and other major adverse cardiovascular outcomes was assessed in each cohort. The PCI-treated patients (n = 1580) were younger, and had better renal function and fewer co-morbidities than non-PCI-treated patients (n = 5052). Cardiovascular mortality was significantly lower in PCI-treated patients as compared with non-PCI-treated patients (7% vs. 16%, P &amp;lt; 0.0001). However, the incidence of non-fatal events was similar in PCI-treated and non-PCI-treated cohorts. There was no statistical difference between the PCI-treated and non-PCI-treated cohorts in the primary or secondary outcomes of the trial. Eplerenone administration, compared with placebo, in the PCI-treated cohort did not affect PCI-related clinical outcomes, including recurrence of angina, the occurrence of acute coronary syndromes, or the need for further revascularization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The beneficial effects of eplerenone in the EPHESUS trial exist for both PCI- and non-PCI-treated AMI patients with LVSD. Eplerenone has minimal, if any, effect upon reducing PCI-related adverse events in the PCI-treated cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.88","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T07:43:14Z","timestamp":1396597394000},"page":"685-691","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Eplerenone in Percutaneous Coronary Intervention-Treated Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Subanalysis of the EPHESUS Trial"],"prefix":"10.1093","volume":"16","author":[{"given":"Javaid","family":"Iqbal","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Science at the University of Sheffield, and Cardiology Department at Sheffield Teaching Hospitals NHS Trust , Sheffield ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Fay","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigation Clinique and Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Adlam","sequence":"additional","affiliation":[{"name":"Department of Cardiology, and NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital , Leicester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Squire","sequence":"additional","affiliation":[{"name":"Department of Cardiology, and NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital , Leicester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasir","family":"Parviz","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Science at the University of Sheffield, and Cardiology Department at Sheffield Teaching Hospitals NHS Trust , Sheffield ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Gunn","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Science at the University of Sheffield, and Cardiology Department at Sheffield Teaching Hospitals NHS Trust , Sheffield ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigation Clinique and Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"2026011921120348300_ejhf88-bib-0001","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011921120348300_ejhf88-bib-0002","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011921120348300_ejhf88-bib-0003","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011921120348300_ejhf88-bib-0004","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011921120348300_ejhf88-bib-0005","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"2026011921120348300_ejhf88-bib-0006","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.HYP.0000172622.51973.f5","article-title":"Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation","volume":"46","author":"Ishizawa","year":"2005","journal-title":"Hypertension"},{"key":"2026011921120348300_ejhf88-bib-0007","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/eurheartj\/ehq254","article-title":"Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans","volume":"32","author":"Thum","year":"2011","journal-title":"Eur Heart J"},{"key":"2026011921120348300_ejhf88-bib-0008","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1210\/jc.2011-1135","article-title":"Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis","volume":"96","author":"Wu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026011921120348300_ejhf88-bib-0009","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/hc3001.091458","article-title":"Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries","volume":"104","author":"Ward","year":"2001","journal-title":"Circulation"},{"key":"2026011921120348300_ejhf88-bib-0010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijcard.2005.03.078","article-title":"Eplerenone suppresses neointimal formation after coronary stent implantation in swine","volume":"107","author":"Wakabayashi","year":"2006","journal-title":"Int J Cardiol"},{"key":"2026011921120348300_ejhf88-bib-0011","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1210\/en.2012-1481","article-title":"Contribution of endogenous glucocorticoids and their intravascular metabolism by 11beta-HSDs to postangioplasty neointimal proliferation in mice","volume":"153","author":"Iqbal","year":"2012","journal-title":"Endocrinology"},{"key":"2026011921120348300_ejhf88-bib-0012","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 focused update: ACCF\/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"},{"key":"2026011921120348300_ejhf88-bib-0013","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011921120348300_ejhf88-bib-0014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011921120348300_ejhf88-bib-0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011921120348300_ejhf88-bib-0016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ejhf.31","article-title":"Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure","volume":"16","author":"Iqbal","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011921120348300_ejhf88-bib-0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","article-title":"Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials","volume":"361","author":"Keeley","year":"2003","journal-title":"Lancet"},{"key":"2026011921120348300_ejhf88-bib-0018","first-page":"743","article-title":"Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial","volume":"360","author":"Fox","year":"2002","journal-title":"Randomized Intervention Trial of unstable Angina. Lancet"},{"key":"2026011921120348300_ejhf88-bib-0019","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure","author":"Montalescot","year":"2013"},{"key":"2026011921120348300_ejhf88-bib-0020","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ahj.2010.06.049","article-title":"Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial","volume":"160","author":"Beygui","year":"2010","journal-title":"Am Heart J"},{"key":"2026011921120348300_ejhf88-bib-0021","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1476-5381.2008.00047.x","article-title":"Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease","volume":"156","author":"Hadoke","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2026011921120348300_ejhf88-bib-0022","first-page":"2519","article-title":"Steroidogenic enzyme gene expression in the human heart","volume":"85","author":"Kayes-Wandover","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2026011921120348300_ejhf88-bib-0023","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","article-title":"Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation","volume":"26","author":"Suzuki","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026011921120348300_ejhf88-bib-0024","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.amjcard.2005.10.017","article-title":"Impact of plasma aldosterone levels for prediction of in-stent restenosis","volume":"97","author":"Amano","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026011921120348300_ejhf88-bib-0025","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","article-title":"Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice","volume":"41","author":"Keidar","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026011921120348300_ejhf88-bib-0026","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/01.HYP.0000128031.31572.a3","article-title":"Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats","volume":"43","author":"Endemann","year":"2004","journal-title":"Hypertension"},{"key":"2026011921120348300_ejhf88-bib-0027","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0008-6363(96)88542-7","article-title":"Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist","volume":"29","author":"Van Belle","year":"1995","journal-title":"Cardiovasc Res"},{"key":"2026011921120348300_ejhf88-bib-0028","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MJT.0b013e31818bec62","article-title":"Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites","volume":"16","author":"Bacchetta","year":"2009","journal-title":"Am J Ther"},{"key":"2026011921120348300_ejhf88-bib-0029","doi-asserted-by":"crossref","first-page":"769","DOI":"10.47102\/annals-acadmedsg.Hurkan","article-title":"Spironolactone does not prevent restenosis after coronary stenting in humans","volume":"33","author":"Kursaklioglu","year":"2004","journal-title":"Ann Acad Med Singapore"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.88","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/16\/6\/685\/66434758\/eurjhf_16_6_685.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/16\/6\/685\/66434758\/eurjhf_16_6_685.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:13:31Z","timestamp":1768875211000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/16\/6\/685\/8427753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,4]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,4,4]]},"published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.88","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,6]]},"published":{"date-parts":[[2014,4,4]]}}}